Online inquiry

IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, Pseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13242MR)

This product GTTS-WQ13242MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & Pseudo-UTP. It ecodes the monoclonal antibody that targets PCSK9 gene. The antibody can be applied in Heterozygous familial hypercholesterolemia (HeFH) research.
Specifications
Product type mRNA
Modified bases Pseudo-UTP
5' Cap Cap 1
Species Humanized
RefSeq NM_174936.4
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 255738
UniProt ID Q8NBP7
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-PCSK9, PF-05335810(Cap 1, Pseudo-UTP, 120 nt-poly(A)) (GTTS-WQ13242MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ5972MR IVTScrip™ mRNA-Anti-IL6, CLLB8(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA CLLB8
GTTS-WQ1854MR IVTScrip™ mRNA-Anti-IL17A, AG1-25(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AG1-25
GTTS-WQ3879MR IVTScrip™ mRNA-Anti-PDCD1, BCD-100(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA BCD-100
GTTS-WQ46MR IVTScrip™ mRNA-Anti-TNFRSF17, 2857916(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA 2857916
GTTS-WQ8757MR IVTScrip™ mRNA-Anti-TNFRSF4, IBI-101(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA IBI-101
GTTS-WQ3317MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ4329MR IVTScrip™ mRNA-Anti-C1S, BIVV009(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA BIVV009
GTTS-WQ5791MR IVTScrip™ mRNA-Anti-EGFR, cetuximab-IR700(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA cetuximab-IR700
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW